Vorbipiprant sodium is under clinical development by Rottapharm Biotech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vorbipiprant sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vorbipiprant sodium overview
Vorbipiprant sodium (CR-6086) is under development for the treatment of rheumatoid arthritis and pMMR-MSS Metastatic Colorectal Cancer, adenocarcinoma of the gastroesophageal junction, gastrointestinal tumor.. It is orally administered as a form of capsule. The drug candidate is a prostaglandin E receptor 4 (EP4 or prostaglandin E2 receptor EP4 subtype) antagonist. It was also under development for osteoarthritis.
Rottapharm Biotech overview
Rottapharm Biotech (Rottapharm), a subsidiary of Fidim Srl is a research company focused on the discovery and development of innovative drugs. The company’s pipeline products include CR4056, 12 ligand for analgesia; CR6086 which is a EP4 receptor antagonist for immunomodulation in RA; CR6086 a EP4 receptor antagonist for immuno-oncology; CR13626 for glioblastoma; CR10049 an Inflammatory OA disease modification; CR14629 which is a metabolic OA disease modification. Rottapharm develops therapies based on its proprietary technology platform for the generation and selection of monoclonal antibodies. Rottapharm is headquartered in Monza, Italy.
For a complete picture of Vorbipiprant sodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
